MedTrace Logo

Eribulin in Brain Metastases From HER2-negative Breast Cancer

NCT03637868 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-05-06

No results posted yet for this study

Summary

To evaluate the efficacy of eribulin for treatment of HER2-negative breast cancer brain metastases (BCBM)

Conditions

Interventions

DRUG

Eribulin

Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Renaud Sabatier, MD · Institut Paoli-Calmettes

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2020-04-14
Completion
2020-04-14

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03637868 on ClinicalTrials.gov